Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (118)
January 4, 2010
- Maurer's Healthcare Insight (117)
December 14, 2009
- Maurer's Healthcare Insight (116)
November 30, 2009
- Maurer's Healthcare Insight (115)
November 16, 2009
- Maurer's Healthcare Insight (114)
October 26, 2009
- Maurer's Healthcare Insight (113)
October 5, 2009
- Maurer's Healthcare Insight (112)
September 14, 2009
- Maurer's Healthcare Insight (111)
August 24, 2009
- Maurer's Healthcare Insight (110)
July 27, 2009
- Maurer's Healthcare Insight (109)
June 22, 2009
- Maurer's Healthcare Insight (108)
May 18, 2009
- Maurer's Healthcare Insight (107)
April 27, 2009
- Maurer's Healthcare Insight (106)
March 30, 2009
- Maurer's Healthcare Insight (105)
March 2, 2009
- Maurer's Healthcare Insight (104)
January 26, 2009
- Maurer's Healthcare Insight (103)
January 5, 2009
- Maurer's Healthcare Insight (102)
December 8, 2008
- Maurer's Healthcare Insight (101)
December 1, 2008
- Maurer's Healthcare Insight (100)
October 27, 2008
- Maurer's Healthcare Insight (99)
September 29, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…